Lokich J J, Skarin A T, Mayer R J, Henderson I C, Blum R H, Frei E
Cancer. 1977 Dec;40(6):2801-5. doi: 10.1002/1097-0142(197712)40:6<2801::aid-cncr2820400608>3.0.co;2-u.
A randomized trial of Adriamycin (A) in combination with melphalan (M), (MA therapy), and in combination with M plus cyclophosphamide (C) (MAC therapy), was initiated in 40 evaluable patients with metastatic breast cancer. Twenty-two patients demonstrated an objective response to therapy: 9/20 to the MA regimen, and 13/20 to the MAC regimen. For the 22 responders, median duration of response is not yet achieved for either complete or partial responders, at 10 and 9 months, respectively. The addition of the two alkylating agents to Adriamycin was superior to the single alkylating agent addition, both in total response rate and in completeness of response. Maintenance therapy, after achieving the maximum cumulative dose of Adriamycin, was provided by cyclophosphamide plus methotrexate and 5-fluorouracil (CMF). In 19 patients completing induction and entering maintenance therapy, only one relapse has developed with maximun follow-up at 15 months.
一项针对40例可评估的转移性乳腺癌患者开展的随机试验，采用阿霉素（A）联合美法仑（M）（MA疗法），以及阿霉素联合M加环磷酰胺（C）（MAC疗法）。22例患者对治疗表现出客观反应：MA方案治疗的20例中有9例有反应，MAC方案治疗的20例中有13例有反应。对于这22例有反应者，完全缓解或部分缓解者的中位反应持续时间分别为10个月和9个月，均未达到。在总反应率和反应完全性方面，在阿霉素基础上加用两种烷化剂均优于仅加用一种烷化剂。在达到阿霉素最大累积剂量后，采用环磷酰胺加甲氨蝶呤和5-氟尿嘧啶（CMF）进行维持治疗。在19例完成诱导治疗并进入维持治疗的患者中，在最长15个月的随访期内仅出现1例复发。
